Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
162.74B
Market cap162.74B
Price-Earnings ratio
10.34
Price-Earnings ratio10.34
Dividend yield
3.41%
Dividend yield3.41%
Average volume
18.04M
Average volume18.04M
High today
$37.19
High today$37.19
Low today
$35.89
Low today$35.89
Open price
$36.31
Open price$36.31
Volume
14.69M
Volume14.69M
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.85
52 Week low$35.85

NVO News

Simply Wall St 1d
Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program

Novo Nordisk (NYSE:NVO) has received an FDA National Priority Voucher tied to a higher dose of its obesity drug Wegovy. This is the fourth such voucher granted...

Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program
24/7 Wall St. 1d
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026

PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026 By Michael Williams Published Mar 28, 7:15AM EDT Quick Read VanEck...

PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
Nasdaq 2d
Novo Nordisk: A Strong Contender in the Pharmaceutical Arena

Explore the exciting world of Novo Nordisk (NYSE: NVO) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below t...

Novo Nordisk: A Strong Contender in the Pharmaceutical Arena

Analyst ratings

61%

of 36 ratings
Buy
30.6%
Hold
61.1%
Sell
8.3%

More NVO News

TipRanks 2d
Novo Nordisk’s EVOKE Plus Alzheimer’s Trial: What the Latest Update Means for NVO Investors

Novo Nordisk (NVO) announced an update on their ongoing clinical study. The EVOKE Plus trial from Novo Nordisk tests whether oral semaglutide can slow early Al...

Nasdaq 2d
Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?

Key Points One of these companies' lineup and pipeline within weight management and outside look much stronger. Valuation does not tip the scale in the other'...

Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?
TipRanks 2d
Novo Nordisk Updates Articles of Association and Capital Increase Mandate

The latest update is out from Novo Nordisk ( (NVO) ). On March 27, 2026, Novo Nordisk A/S filed an updated set of Articles of Association outlining its corpora...

Simply Wall St 2d
Is Novo Nordisk Now Attractive After Recent Share Price Weakness?

If you are wondering whether Novo Nordisk’s current share price offers value or carries more risk than reward, it starts with understanding how the market is no...

Is Novo Nordisk Now Attractive After Recent Share Price Weakness?
Benzinga 2d
Novo Nordisk Wins FDA Nod For First-Ever Weekly Basal Insulin​

The company positioned the therapy as a shift in diabetes care, potentially reducing the burden of daily injections while maintaining glycemic control. FDA Cle...

Novo Nordisk Wins FDA Nod For First-Ever Weekly Basal Insulin​
TipRanks 3d
Buy Rating on Hims & Hers: Undervalued Growth Leveraging Novo Nordisk GLP-1 Partnership and Scale Advantages

Hims & Hers Health, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Maria Ripps from Canaccord Genuity maintained a Buy...

Nasdaq 3d
Hims & Hers Expands Access To Novo Nordisk's FDA-Approved GLP-1 Medications, Including Wegovy Pill

(RTTNews) - Hims & Hers Health Inc. (HIMS) announced that a wide range of Novo Nordisk's FDA-approved GLP-1 medications are now available to eligible customers....

Hims & Hers Expands Access To Novo Nordisk's FDA-Approved GLP-1 Medications, Including Wegovy Pill

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.